Ascendis Pharma (ASND) PT Raised to $201 at Cantor Fitzgerald
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- US stock futures mixed as Apple slides, midterms loom
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ASND Hot Sheet
Price: $248.98 --0%
Rating Summary:
23 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 15 | New: 12
Rating Summary:
23 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 15 | New: 12
Join SI Premium – FREE
Cantor Fitzgerald analyst Alethia Young raised the price target on Ascendis Pharma (NASDAQ: ASND) to $201.00 (from $185.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Community Health (CYH) PT Lowered to $1 at Wells Fargo
- Victoria Secret (VSXY) PT Raised to $120 at Wells Fargo
- Tempus AI Inc (TEM) PT Raised to $120 at Mizuho
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
